Welcome to our dedicated page for Red Light Hollan news (Ticker: TRUFF), a resource for investors and traders seeking the latest updates and insights on Red Light Hollan stock.
Red Light Holland Corp (TRUFF) generates news across functional mushrooms, psilocybin truffles, retail distribution, research collaborations, and treasury strategy. The company describes itself as an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal recreational market within the Netherlands, in compliance with all applicable laws.
News updates frequently cover financial and operational results, where Red Light Holland reports on cash balances, revenue trends, and performance of its various business units. These releases often include commentary on management’s priorities, such as streamlining operations, evaluating non-core assets, and exploring mergers and acquisitions that could support its mushroom and psilocybin-related activities.
Another major news theme is research and development in psilocybin. Articles detail the company’s partnership with Irvine Labs Inc., an FDA-compliant and DEA-registered facility in California, including shipments of naturally occurring psilocybin truffles from the Netherlands under United States Controlled Substances import permits, potency testing, Certificates of Analysis, and work on proprietary dehydration and packaging processes. Updates also highlight collaborations like the Psychedelic Genome Project at Arizona State University and the appointment of a scientific advisor in psychedelic neuroscience.
Red Light Holland news also follows consumer and retail milestones, such as Happy Caps Mushroom Farm’s expansion into Safeway stores in Oregon and Washington State, seasonal retail programs, and the launch of functional mushroom gummies on Amazon and in Canadian supermarkets. Additional coverage addresses the company’s Bitcoin balance sheet strategy, including purchases of Bitcoin exchange-traded fund shares and work with cryptocurrency advisors.
Investors and observers can use the TRUFF news feed to review earnings announcements, R&D progress, retail distribution developments, and strategic updates as the company reports them.
Red Light Holland (OTCQB: TRUFF) said it will support UCSF's Carhart-Harris Lab Global Psychedelic Study by directing researchers and clinicians receiving Filament Health's psilocybin candidate PEX010 on how to join the large-scale online study.
Filament has supplied PEX010 to over 70 trials worldwide and is authorized for use in several federally authorized compassionate use programs.
Red Light Holland (OTCQB: TRUFF) and Filament Health (OTC: FLHLF) received an Interim Order from the Supreme Court of British Columbia advancing Red Light's proposed statutory plan of arrangement to acquire Filament.
The order authorizes a Filament shareholder meeting on April 24, 2026; Filament's board unanimously recommends approval. Filament shareholders of record on March 2, 2026 may vote. Completion remains subject to shareholder, court and regulatory approvals.
Red Light Holland (OTCQB:TRUFF) engaged Kala Bio's Researgency.ai to support clinical development of Filament Health's patented botanical psilocybin candidate PEX010.
The company announced a definitive arrangement to acquire Filament's business, including 76 issued patents across 15 families, noted PEX010 has Health Canada and FDA trial authorizations, positive Phase 2 data in alcohol use disorder, and supply to >70 clinical sites.
Red Light Holland (OTCQB: TRUFF) will acquire Filament Health via a statutory plan of arrangement, combining Filament's GMP manufacturing, Health Canada Dealer's Licence, FDA‑authorized clinical programs and 76 issued patents with Red Light's mass cultivation, brand presence and microdosing data.
The all‑share deal issues up to 182,447,452 consideration shares, leaves existing Red Light holders with ~70% post‑closing, and targets closing in Q2 2026 subject to approvals.
Red Light Holland (OTCQB: TRUFF) will acquire Filament Health by plan of arrangement to combine GMP pharmaceutical manufacturing, a Health Canada Level 8 Dealer's Licence, an FDA-authorized clinical program and 76 issued patents covering natural psilocybin technologies.
The all-share transaction issues up to 182,447,452 Consideration Shares, leaves existing Red Light shareholders with ~70% ownership post-close, and targets completion in Q2 2026.
Red Light Holland (OTCQB: TRUFF) reported Q3 2026 results for the three and nine months ended December 31, 2025, with total cash of $9.238M and revenue of $1.265M for the quarter (up 8.3% year-over-year). Gross profit fell to $0.358M (down 13.7% YoY) while G&A expenses declined 15.8%. The company ceased shiitake production at AEM and is pursuing strategic R&D, M&A evaluations, and distribution growth, including Netherlands truffle sales to over 125 retailers and expanded U.S. retail activity with Albertsons/Safeway.
Red Light Holland (OTCQB:TRUFF) reported Q2 2026 results and a corporate update for the quarter ended September 30, 2025. Key metrics: Revenue $0.754M (down 44.9% YoY), Gross profit $0.327M (down 68.7% YoY), Adjusted EBITDA loss $0.785M (worse 61.9% YoY), Cash $10.226M, Total assets $19.018M.
Operational highlights include expanded U.S. retail distribution with Albertsons/Safeway, new R&D milestones with DEA-registered Irvine Labs (5kg shipment; potency testing compatible with manufacturing), ASU collaboration, and appointment of Dr. Robin Carhart-Harris as scientific advisor. Company pursuing M&A, streamlining, and a Bitcoin allocation up to $2M.
Red Light Holland (OTCQB: TRUFF) announced that its FDA‑compliant, DEA‑registered partner Irvine Labs in California received a second, larger 5 kg shipment of naturally occurring psilocybin imported under a United States Controlled Substances import permit on November 19, 2025.
The shipment was processed under Irvine Labs' 2025 DEA quota after potency testing and process validation confirmed compatibility with medical‑grade manufacturing. The companies said this scale‑up will support expanded R&D toward standardized psilocybin products and clinical/therapeutic programs. The company also issued 3,250,719 common shares at a deemed price of $0.035 per share to arm's length creditors.
Red Light Holland (OTCQB: TRUFF) announced that its wholly owned subsidiary Happy Caps expands distribution with Albertsons Companies' Safeway banner to 123 stores across Oregon and Washington, up from 66 stores, with rollout the week of November 17, 2025 and a replenishment order the week of December 5, 2025 for the holiday season.
Key metrics: 4,428 units to be supplied (up from 2,376), locally produced in Oregon with Trailbridge Mushroom Farm, featuring Shiitake, Lion's Mane, and Oyster home grow kits. The release also discloses equity actions: 100,000 stock options at $0.05, 4,250,000 RSUs, and issuance of 5,611,250 shares to settle debt at $0.035 per share, including related-party RSU and share participation.
Red Light Holland (OTCQB: TRUFF) announced that its FDA‑compliant, DEA‑registered partner Irvine Labs received a second United States Controlled Substances import permit on October 14, 2025, authorizing the import equivalent to 5 kg of psilocybin truffles from Red Light Holland's Netherlands facility.
The company said this follows a Certificate of Analysis confirming psilocybin potency and process validation in September 2025 and will support expanded R&D into dehydration, packaging, shelf‑life extension, and standardized microdosing capsule development for potential medical‑grade manufacturing, government pilot programs, and clinical trials.